QNZ46 is a noncompetitive and voltage-independent antagonist selective for NR2C/D containing NMDA receptors (IC50 = 6, 3, 229, and >300 M for NR2C, NR2D, NR2A, and NR2B, respectively). Inhibition on NR2C/D containing NMDA receptors is glutamate-binding, but not glycine-binding, dependent.
仅供研究使用。 我们不向患者出售。
化学信息
名称 | QNZ46 |
Iupac 化学名称 | 4-[6-Methoxy-2-[(1E)-2-(3-nitrophenyl)ethenyl]-4-oxo-3(4H)-quinazolinyl]-benzoic Acid |
同义词 | QNZ-46 |
英文同义词 | QNZ-46 |
分子式 | C24H17N3O6 |
分子量 | 443.408 |
Smile | COC=1C=C2C(N(C(=NC2=CC1)\C=C\C1=CC(=CC=C1)[N+](=O)[O-])C1=CC=C(C(=O)O)C=C1)=O |
InChiKey | GNLVJIICVWDSNI-LFYBBSHMSA-N |
InChi | InChI=1S/C24H17N3O6/c1-33-19-10-11-21-20(14-19)23(28)26(17-8-6-16(7-9-17)24(29)30)22(25-21)12-5-15-3-2-4-18(13-15)27(31)32/h2-14H,1H3,(H,29,30)/b12-5+ |
Cas号 | 1237744-13-6 |
相关CAS号 | |
外观性状 | Solid powder |
纯度 | 98% |
存储 | -20 ºC for 3 years |
可溶性 | Soluble in DMSO |
处理方式 | |
运输条件 | Shipped under ambient temperature |
海关编码 | |
Targets | |
Mechanism | |
Cell study | |
Animal study | |
Clinical study | |